Tarrytown, N.Y.-based biotech company Regeneron secured $450 million from Operation Warp Speed, the White House's task force to expedite COVID-19 vaccine development, to manufacture thousands of doses of its antibody cocktail.
The deal comes one day after the drugmaker announced it was entering late-stage testing for REGN-COV2, its experimental COVID-19 antibody treatment.
The trials are testing multiple dosages to discover the exact amount of treatment doses that should be produced. Regeneron estimates between 70,000 and 300,000 doses could become available, starting as soon as the end of summer.